Many clinical trial status discrepancies identified between ClinicalTrials.gov and EUCTR

Approximately one sixth of clinical trials registered on both ClinicalTrials.gov and the EU Clinical Trials Register (EUCTR) have discrepancies in their completion status, according to a study published March 7, 2018 in the open-access journal PLOS ONE by Jessica Fleminger and Ben Goldacre from the University of Oxford, UK.

Trial registries are important sources of information for clinicians and researchers, since they provide information on what trial results are pending or already available. While building OpenTrials, an open database that aims to link all publicly available information from all clinical trial registries, the authors of this study identified multiple errors, omissions and discrepancies between different registries. These differences prompted the researchers to investigate the prevalence of incorrect completion statuses between two major registries, the EU Clinical Trials Register (EUCTR) and ClinicalTrials.gov.

The researchers analyzed 10,492 clinical trials that were registered on both ClinicalTrials.gov and EUCTR, examining their trial completion status and reporting status for discrepancies. They found that 16.2% of dual registered trials had discrepant completion statuses and 33.9% of dual-registered trials listed as 'ongoing' on EUCTR were listed as 'completed' on ClinicalTrials.gov.

The researchers suggest that the prevalence of incorrect statuses on trial entries could mean that they are excluded from studies looking at publication bias or systematic reviews pooling together clinical data from different clinical trials. While it is unclear whether researchers, registry owners, or both are responsible for the errors, the authors recommend that researchers identifying discrepancies should request clarifications from the trialists, and registry owners should undertake simple cross-checks of data to ensure that the completion status is accurate.

"Trial registries are important public documents: doctors, researchers, and patients rely on the information that trialists post about their clinical trial," says Ben Goldacre. "Concerningly, we now show that this data is commonly inaccurate."

Jessica Fleminger, Ben Goldacre.
Prevalence of clinical trial status discrepancies: A cross-sectional study of 10,492 trials registered on both ClinicalTrials.gov and the European Union Clinical Trials Register.
PLoS ONE 13(3): e0193088. doi: 10.1371/journal.pone.0193088.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...